The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma
暂无分享,去创建一个
U. Dirksen | M. Paulussen | H. Juergens | R. Ladenstein | A. Ranft | A. Smets | B. Brichard | J. Merks | S. Klco-Brosius | J. Kruseová | L. Haveman | T. Kuehne | H. vd Berg
[1] A. Degnan,et al. Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. , 2018, Clinical imaging.
[2] A. Moreau,et al. Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma , 2017, PloS one.
[3] U. Dirksen,et al. Management and Outcome of Ewing Sarcoma of the Head and Neck , 2016, Pediatric blood & cancer.
[4] H. Daldrup-Link,et al. Three-dimensional Radiologic Assessment of Chemotherapy Response in Ewing Sarcoma Can Be Used to Predict Clinical Outcome. , 2016, Radiology.
[5] K. Hess,et al. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. , 2015, International journal of radiation oncology, biology, physics.
[6] H. Lederman,et al. Magnetic Resonance Imaging in Pediatric Bone Tumors , 2014, Current Radiology Reports.
[7] U. Dirksen,et al. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. McHugh,et al. Response assessment in pediatric rhabdomyosarcoma: can response evaluation criteria in solid tumors replace three-dimensional volume assessments? , 2013, Radiology.
[9] Lihua Chen,et al. The Correlation between Apparent Diffusion Coefficient and Tumor Cellularity in Patients: A Meta-Analysis , 2013, PloS one.
[10] U. Dirksen,et al. Ewing Sarcoma: Biology-Based Therapeutic Perspectives , 2012, Pediatric hematology and oncology.
[11] L. Schwartz,et al. Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] U. Dirksen,et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] James R. Anderson,et al. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Craft,et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO‐E.W.I.N.G. 99 clinical trial , 2006, Pediatric blood & cancer.
[15] H. Brisse,et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment , 2004, Pediatric Radiology.
[16] J. Bloem,et al. Monitoring the effect of chemotherapy in Ewing's sarcoma of bone with MR imaging , 1994, Skeletal Radiology.
[17] G. Delling,et al. Morphological grades of regression in osteosarcoma after polychemotherapy — Study COSS 80 , 2004, Journal of Cancer Research and Clinical Oncology.
[18] B. Bui,et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study) , 2001, British Journal of Cancer.
[19] W. Reddick,et al. Tumor volume or dynamic contrast-enhanced MRI for prediction of clinical outcome of Ewing sarcoma family of tumors , 2001, Pediatric Radiology.
[20] A. Craft,et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Dalinka,et al. Magnetic resonance imaging in primary bone tumors. , 2000, Seminars in roentgenology.
[22] E. Gehan,et al. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? , 2000, Journal of the National Cancer Institute.
[23] D. Vanel,et al. Imaging Evaluation of the Response of High-Grade Osteosarcoma and Ewing Sarcoma to Chemotherapy with Emphasis on Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2000, Seminars in musculoskeletal radiology.
[24] P. Pynsent,et al. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma , 1999 .
[25] J. Bloem,et al. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities , 1998, Skeletal Radiology.
[26] S. Ferrari,et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] C. R. Pinkerton,et al. Ewing sarcoma: MR imaging of chemotherapy-induced changes with histologic correlation. , 1992, Radiology.
[28] R. Souhami,et al. MRI in primary bone tumors: therapeutic implications. , 1991, European Journal of Radiology.
[29] W. Meyer,et al. Use of MR imaging to assess results of chemotherapy for Ewing sarcoma. , 1990, AJR. American journal of roentgenology.
[30] J. Bloem,et al. Radiologic staging of primary bone sarcoma: MR imaging, scintigraphy, angiography, and CT correlated with pathologic examination. , 1988, Radiology.
[31] J. Michaelis,et al. Prognostic factors in the treatment of Ewing's sarcoma. The Ewing's Sarcoma Study Group of the German Society of Paediatric Oncology CESS 81. , 1987, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.